Millions of Brits with eczema are almost twice as likely to suffer agonising eye and bowel conditions, research suggests. Research has long suggested that the common skin condition, known ...
Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious ...
Corvus Pharma (CRVS) stock surges as the company plans a Phase 2 trial for its lead asset against eczema following ...
New Guidance Helps Parents Understand Infant Skin Vulnerability and Bacterial Imbalance A child's eczema severity often ...
The condition can be uncomfortable and create a sense of social embarrassment among sufferers For the one in 10 adults who will develop eczema at some point in their lifetime, and one in five children ...
Analyzing patient health care notes recorded during millions of medical appointments at GPs and hospitals across England has ...
"I always felt like there was just something wrong with me," Michelle Smith told Newsweek, after years of struggling with ...
Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease mechanisms including IL-13 and therefore makes targeting IL-13 with lebrikizumab a ...
Antihypertensive drugs are associated with a small increased risk for eczematous dermatitis in older adults, with the highest association seen for diuretics and calcium channel blockers, in a ...
There’s a reason why cosmetics is a billion-dollar industry in the United States alone — because purchasing (and trying out) modern-day beauty products makes us feel good. So many shades, so many ...
Investing.com -- Corvus Pharmaceuticals (NASDAQ:CRVS) stock surged 48% Tuesday morning following the company’s announcement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback